BioNTech SE (BNTX)
| Market Cap | 37.72B |
| Revenue (ttm) | 588.20M |
| Net Income (ttm) | 18.53M |
| Shares Out | 241.52M |
| EPS (ttm) | 0.07 |
| PE Ratio | 2,308.98 |
| Forward PE | 16.72 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $168.95 |
| Previous Close | $161.80 |
| Change ($) | 7.15 |
| Change (%) | 4.42% |
| Day's Open | 164.99 |
| Day's Range | 164.80 - 176.00 |
| Day's Volume | 4,680,735 |
| 52-Week Range | 43.00 - 176.00 |
Money and pipelines are the two most important factors in picking the most likely to succeed.
This small-cap biotech is currently trailing its rivals in the coronavirus vaccine race. Could a comeback be in the cards?
AstraZeneca's pain is resulting in a big gain for Pfizer and BioNTech.
BioNTech's mRNA vaccine pioneer says third Pfizer dose is likely
CNBC's Kelly Evans discusses mass vaccination and fighting the Covid pandemic with Dr. Ozlem Tureci, BioNTech chief medical officer and co-founder. For access to live and exclusive video from CNBC subsc...
The chief medical officer of BioNTech told CNBC that people will likely need a third shot of its two-dose Covid-19 vaccine as immunity against the virus wanes.
EU says J&J vaccine benefits outweigh risks, plus Pfizer finds fake COVID-19 shots
Yahoo Finance's Anjalee Khemlani reports on European regulators finding a possible blood clot link with the Johnson & Johnson vaccine, but say the benefits outweigh the risks. Meanwhile, Pfizer identifi...
The European Commission exercises its option to purchase an additional 100 million doses of Pfizer (PFE)/ BioNTech's COVID-19 vaccine, Comirnaty, for EU member states.
NEW YORK and MAINZ, GERMANY, April 19, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the ...
Pfizer is a lot more than the covid vaccine. PFE stock has strong growth potential and is a great dividend stock for 2021.
Pfizer CEO says a third vaccine dose is likely, Moderna updates booster shot timeline
Pfizer CEO sees need for a third vaccine dose as Moderna updates its timeline on third booster shot. Pause on the Johnson & Johnson vaccine remains.
Studies are still under way to determine whether additional booster shots are needed to maintain immunity, but Pfizer's CEO calls it "a likely scenario."
Pfizer to Raise EU Vaccine Supply by 25%
Apr.14 -- Eurasia Group Global Health Special Advisor Scott Rosenstein speaks to Bloomberg's and Alix Steel about Pfizer's increased vaccine supply and the vaccination rate in Europe on "Bloomberg Marke...
A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.
Millions of kids could soon be allowed to receive Pfizer's COVID-19 vaccine. Will the big drugmaker make some big bucks this year?
Bad news for J&J could be good news for these biotechs.
Johnson & Johnson's (NYSE: JNJ) pain has proved to be gain for other vaccine companies, including BioNTech SE (NASDAQ: BNTX), Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA) and Novavax, Inc. (NAS...
It can already claim it contributed to both companies' COVID vaccines.
It's possible.
South African Variant Able To Elude Pfizer/BioNTech' Vaccine Protection, Israeli Study Shows: Report
According to a real-world data study in Israel, the coronavirus variant discovered in South Africa may dodge the protection provided by Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vac...
Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appe...
South African Covid variant may evade the Pfizer vaccine, according to Israeli study
The coronavirus variant first discovered in South Africa may be able to evade some of the protection of the Pfizer-BioNTech vaccine, according to a new Israeli study. The researchers found the prevalenc...
BioNTech SE Sponsored ADR (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ne...
The coronavirus variant first discovered in South Africa is able to evade some of the protection of the Pfizer-BioNTech vaccine, according to an Israeli study.
If investors are expecting BNTX stock to continue generating double digit gains, they should be taking a careful look at its pipeline. The post What Can BioNTech Do for an Encore?
The European Commission is reportedly seeking EU governments' approval to get into talks with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to purchase up to 1.8 billion doses of their COVID-19 ...
Pfizer files to expand Covid vaccine EUA down to age 12
CNBC's Meg Tirrell reports on Pfizer's latest filing to expand its vaccine authorization to adolescents.
Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.
Why Didn't Pfizer and BioNTech Stocks Soar After Their COVID Vaccine Achieved 100% Efficacy in Kids?
There are several potential reasons why investors didn't cheer the companies' great news more loudly.
The National Institutes of Health (NIH) has begun a mid-stage study to determine the risk of allergic reactions shortly after receiving COVID-19 vaccines made by Moderna Inc (NASDAQ: MRNA) and Pfizer In...
Look for sales of the vaccine to be better than expected, too.
Investors may be wondering what comes next for BioNTech SE (NASDAQ:BNTX). That is, what does the German company have behind its Covid-19 vaccine, which it says will generate revenue of $11.5 billion thi...
Pfizer Inc (NYSE: PFE) is reportedly working on a new COVID-19 vaccine supply deal to Israel after an initial agreement announced in late 2020 has ended. “The company is currently working with the Israe...
Out of a limited number of earnings reports released in this shortened week, we'll recap here the impact of the week's five best reports.
Pfizer's Covid-19 vaccine is effective against South African variant
CNBC's Meg Tirrell reports Pfizer's Covid-19 vaccine is effective against the more contagious South African Covid variant. Pfizer's vaccine is also effective for 6 months, according to clinical trials.
Top-line results from clinical trials also show the jab protects against the so-called South African variant.
In a joint statement on Thursday, Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX) said new data showed their Coronavirus vaccine had an efficacy of over 91% after six months. Initially, in November, ...
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 2% after the company confirms high efficacy and no serious safety concerns through up to six months following the second dose in the updated...
Pfizer and Biontech vaccines show strong efficacy against severe disease
#J&Jvaccine Yahoo Finance's Anjalee Khemlani and Myles Udland discuss the latest on Pfizer and Biontech showing strong efficacy against severe disease, plus a batch of Jonhson and Johnson COVID-19 vacci...
Investors may want to consider the following securities as their forward price-earnings ratios are lower than the S&P 500's historical average of 15. The projections of future earnings are based on data...
BioNTech stock continued a sprint Thursday after the company suggested its Pfizer-partnered Covid vaccine is effective against a mutation first identified in South Africa. The post Pfizer Suggests Covid...
The shares of Pfizer Inc. (NYSE:PFE) are down 0.2% at $36.15 at last check, despite the drug maker posting updated results that showed its Covid-19 vaccine, in partnership with BioNTech (BNTX), is 91% e...
The vaccine has been okayed for emergency use in the U.S. for people aged 16 or older.
Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.
New York and Mainz, Germany, April 1, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 o...
Coronavirus: Pfizer says vaccine is 100% effective in kids 12-15, France goes into another lockdown
Yahoo Finance's Anjalee Khemlani reports on the latest coronavirus news including France going into another lockdown, US health officials voicing concern about a 4th wave, and Pfizer reporting COVID-19 ...
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
The companies plan to apply for emergency use authorization in adolescents in the coming weeks.
The company and its partner Pfizer reported 100% efficacy for their COVID-19 vaccine in kids ages 12 to 15.
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small ce... [Read more...]
| Industry Biotechnology | IPO Date Oct 10, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol BNTX |
Analyst Forecasts
According to 10 analysts, the average rating for BioNTech SE stock is "Buy." The 12-month stock price forecast is 129.18, which is a decrease of -23.54% from the latest price.